Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocatinlimab in moderate-to-severe atopic dermatitis
NCT05651711Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Rocatinlimab with Placebo (2 arms). Primary endpoints: Validated Investigator's Global Assessment for AD 0/1 Response at 24 weeks and Eczema Area and Severity Index 75% Reduction at 24 weeks. Started Dec 2022; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05651711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651711.